Baxter International Inc (NYSE:BAX) has been given a consensus recommendation of “Buy” by the seventeen analysts that are covering the firm, MarketBeat Ratings reports. Seven research analysts have rated the stock with a hold recommendation, eight have issued a buy recommendation and two have given a strong buy recommendation to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $70.23.
BAX has been the subject of a number of analyst reports. Evercore ISI initiated coverage on shares of Baxter International in a report on Wednesday, January 3rd. They issued an “outperform” rating and a $71.00 price objective for the company. Bank of America raised shares of Baxter International from a “neutral” rating to a “buy” rating in a report on Tuesday, January 2nd. Raymond James Financial raised shares of Baxter International from a “market perform” rating to an “outperform” rating and set a $73.00 price objective for the company in a report on Wednesday, January 3rd. Stifel Nicolaus reissued a “hold” rating and issued a $65.00 price objective on shares of Baxter International in a report on Thursday, October 26th. Finally, Zacks Investment Research lowered shares of Baxter International from a “buy” rating to a “hold” rating in a report on Tuesday, December 26th.
In other Baxter International news, SVP Jeanne K. Mason sold 33,350 shares of the stock in a transaction dated Monday, December 4th. The shares were sold at an average price of $65.25, for a total transaction of $2,176,087.50. Following the completion of the transaction, the senior vice president now owns 124,609 shares of the company’s stock, valued at $8,130,737.25. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, SVP Giuseppe Accogli sold 28,641 shares of the stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $67.00, for a total transaction of $1,918,947.00. The disclosure for this sale can be found here. Company insiders own 0.05% of the company’s stock.
Shares of Baxter International (BAX) opened at $65.00 on Tuesday. The company has a debt-to-equity ratio of 0.37, a current ratio of 2.80 and a quick ratio of 2.22. Baxter International has a 1-year low of $48.58 and a 1-year high of $72.58. The stock has a market cap of $35,410.00, a PE ratio of 50.00, a P/E/G ratio of 1.82 and a beta of 0.78.
Baxter International (NYSE:BAX) last announced its quarterly earnings data on Thursday, February 1st. The medical instruments supplier reported $0.64 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.59 by $0.05. Baxter International had a net margin of 6.79% and a return on equity of 15.12%. The firm had revenue of $2.77 billion during the quarter, compared to analyst estimates of $2.77 billion. During the same quarter in the prior year, the firm posted $0.57 earnings per share. Baxter International’s quarterly revenue was up 4.9% on a year-over-year basis. research analysts expect that Baxter International will post 2.78 EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: “Baxter International Inc (BAX) Receives Average Recommendation of “Buy” from Analysts” was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this article on another publication, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this article can be viewed at https://www.americanbankingnews.com/2018/02/13/baxter-international-inc-bax-receives-average-recommendation-of-buy-from-analysts.html.
About Baxter International
Baxter International Inc, through its subsidiaries, provides renal and hospital products. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures sterile intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics and biosurgery products.
Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.